[August 25, 2014]

Research and Markets: Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

Research and Markets (http://www.researchandmarkets.com/research/ddhrxk/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM" report to their offering.

The Glioblastoma Multiforme (GBM) therapeutics market in the four Asia-Pacific (APAC) markets of Australia, China, India and Japan was worth $49.4m in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.5% to $105.8m by 2020. Japan was the largest of these markets in 2013, valued at $23.8m, equivalent to a share of 48%, closely followed by China at $19.7m or 40%. This significant expected growth is due to the probable approval and market entries of Rindopepimut (CDX-110), Cotara (TNT-1) and Avastin (bevacizumab) in some of the APAC regions during the forecast period.

India and Australia have more promising candidates for possible approval in the forecst period than China and Japan. The growth forecast for Japan, however, is still high, even though it has just one candidate in late-stage development that could be approved during the forecast period, due to recent approval of Avastin. Japan is expected to post a high CAGR of 13.8%, second only to India among the APAC countries. The GBM market in India is currently the smallest, estimated at $4.6m in 2013, but is expected to post the highest growth, at a CAGR of 14.4% until 2020. There are four promising GBM drugs in the pipeline in India that could have a significant impact on market growth - Rindopepimut and BIOMAb (nimotuzumab) for newly diagnosed GBM; Avastin and Cotara for treatment in the recurrent setting.

The pipeline presents two promising novel therapies - Rindopepimut and Cotara - that could have a significant bearing on the GBM market in the APAC region. Phase II studies of Rindopepimut demonstrated a relatively high median Overall Survival (OS), and a significant survival benefit when compared to historic controls treated with the standard of care. However, the vaccine is limited to the 30% of GBM patients who are Epidermal Growth Factor Receptor (EGFR) variant (v) III-positive. Phase II studies of Cotara showed similar OS to Avastin, with slightly better Progression Free Survival (PFS) improvement in recurrent GBM. As a single-infusion therapy, Cotara is likely to become a good alternative second-line treatment.

Key Topics Covered:

1 Tables & Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Introduction

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Marketed Products

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Deals and Strategic Consolidations

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Appendix

For more information visit http://www.researchandmarkets.com/research/ddhrxk/glioblastoma

[ Back To TMCnet.com's Homepage ]